Those who plot the destruction of others often fall themselves. [Lat., Saepe intereunt aliis meditantes necem.]
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$EPAZ with lots of DD to sort thru, this is an afternoon runner !!!
$EPAZ in a loading zone !!
Epazz Inc. (EPAZ) is an enterprise-wide software company specializing in providing customized Web applications to the corporate world, higher education institutions, and the public sector.
Epazz’ unique BoxesOS applications can create virtual communities for enhanced communication, provide information and content for decision-making, and create a secure marketplace for any type of commerce all through the medium of the Internet.
Epazz was founded by Shaun Passley in February 1999 who saw the need and benefits of integrated Web-based applications for the increasing demand of relevant and timely information for personal and business management. Today his vision has expanded to include the business world and the public sector as well as higher education institutions.
$EPAZ needing some buying pressure...thin !!
Texas Wyoming Drilling (TWDL) up 15.56% !!!
Volume: 935,424
PLPL with a nice move back up from that dip..
$EPAZ an afternoon mover, time to get in !
$EPAZ trying to gain traction !!
EPAZ looking for more volume it's still early...
$EPAZ, check it out...can run today !
$EPAZ looking to hit the .0006's today !
$EPAZ on Alert !! Volume comes in early this will move quickly...
PLPL on HIGH ALERT ! Bottom play...this has huge swings and is due !!
$EPAZ on ALERT ! can hit the 6's easily today !
Good morning EPAZ !
Good morning PLPL !
Good morning Everyone !!
Texas Wyoming Drilling (TWDL) up 12.50% !!
Volume: 545,924
PLPL bottomed, this will hopefully pick back up this afternoon !
And for the record, it's a down day for the market as a whole, so load up, imo...PLPL could be huge!!!
PLPL will, as Always, bounce back...great entry point here as this will move up before the eod !!
$ECDP, keep it on your Radar !!!
Good morning ECDP !
GM Homie-G !! Watch PLPL bounce big today, another money maker !!
Plandai Biotechnology, Inc. Qualifies for Grant From South African Department of Trade & Industry
2014-04-08 08:55 ET - News Release
SEATTLE, WA(eTeligis.com)
Planda Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has qualified for and submitted the necessary paperwork to receive a grant from the South African Department of Trade and Industry (DTI). DTI grants are awarded based on qualifications relating to capital investment in new industry. The Company's extraction and processing factory in the Mpumalanga province in northern South Africa is considered a qualifying facility. DTI representatives will be touring the facility in the first week of May.
According to the DTI website (http://www.thedti.gov.za/about_dti.jsp), their strategic objective is to facilitate transformation of the economy to promote industrial development, investment, competitiveness and employment creation. The grant for which Planda qualifies is based on a fixed percentage of actual capital invested in the project. Depending on the final cost of the Senteeko manufacturing facility and the percentage of award as determined by the legislature, the grant is expected to be between 14-26 million Rands ($1.3-2.5 million US). The final amount is expected to be determined over the coming 90 days with the award being paid later in 2014.
Chairman and Chief Executive Officer Roger Duffield commented, "The South African government has been among our strongest supporters, first with the $13 million government-backed loan from the Land and Agriculture Bank, and now with an additional $1.3 to $2.5 million grant to help defray the cost of building our production facility. It is a testament to their belief not only in our technology but also our efforts to revitalize the region by creating jobs and operating under a zero carbon footprint model. The grant money will be useful in supporting our operations as the factory comes online and sales begin to ramp up in the coming months."
Planda first product to market will be Phytofare Catechin Complex, which includes the entire catechin profile derived from live green tea that is grown and processed on the Company's 8,000 acre Senteeko estate in South Africa. Later in 2014, and pending the results of a human clinical trial for treating cold and flu symptoms, the Company will begin producing Phytofare Limonoid Glycoside Complex, which contains citrus bioflavonoids that will also be extracted at the Senteeko facility using lemons bought from neighboring farms until its own lemon trees reach maturity.
About Planda Biotechnology, Inc.
Planda Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Planda Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Safe Harbor Statement
The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Planda's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Planda is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.
Contact: Andrew BeyerPhone: 888-627-6902Email: investor@Plandabiotech.com
SOURCE: Plandai Biotechnology, Inc.
Plandai Biotechnology, Inc. Qualifies for Grant From South African Department of Trade & Industry
2014-04-08 08:55 ET - News Release
SEATTLE, WA(eTeligis.com)
Planda Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has qualified for and submitted the necessary paperwork to receive a grant from the South African Department of Trade and Industry (DTI). DTI grants are awarded based on qualifications relating to capital investment in new industry. The Company's extraction and processing factory in the Mpumalanga province in northern South Africa is considered a qualifying facility. DTI representatives will be touring the facility in the first week of May.
According to the DTI website (http://www.thedti.gov.za/about_dti.jsp), their strategic objective is to facilitate transformation of the economy to promote industrial development, investment, competitiveness and employment creation. The grant for which Planda qualifies is based on a fixed percentage of actual capital invested in the project. Depending on the final cost of the Senteeko manufacturing facility and the percentage of award as determined by the legislature, the grant is expected to be between 14-26 million Rands ($1.3-2.5 million US). The final amount is expected to be determined over the coming 90 days with the award being paid later in 2014.
Chairman and Chief Executive Officer Roger Duffield commented, "The South African government has been among our strongest supporters, first with the $13 million government-backed loan from the Land and Agriculture Bank, and now with an additional $1.3 to $2.5 million grant to help defray the cost of building our production facility. It is a testament to their belief not only in our technology but also our efforts to revitalize the region by creating jobs and operating under a zero carbon footprint model. The grant money will be useful in supporting our operations as the factory comes online and sales begin to ramp up in the coming months."
Planda first product to market will be Phytofare Catechin Complex, which includes the entire catechin profile derived from live green tea that is grown and processed on the Company's 8,000 acre Senteeko estate in South Africa. Later in 2014, and pending the results of a human clinical trial for treating cold and flu symptoms, the Company will begin producing Phytofare Limonoid Glycoside Complex, which contains citrus bioflavonoids that will also be extracted at the Senteeko facility using lemons bought from neighboring farms until its own lemon trees reach maturity.
About Planda Biotechnology, Inc.
Planda Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Planda Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Safe Harbor Statement
The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Planda's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Planda is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.
Contact: Andrew BeyerPhone: 888-627-6902Email: investor@Plandabiotech.com
SOURCE: Plandai Biotechnology, Inc.
Plandai Biotechnology, Inc. Qualifies for Grant From South African Department of Trade & Industry
2014-04-08 08:55 ET - News Release
SEATTLE, WA(eTeligis.com)
Planda Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has qualified for and submitted the necessary paperwork to receive a grant from the South African Department of Trade and Industry (DTI). DTI grants are awarded based on qualifications relating to capital investment in new industry. The Company's extraction and processing factory in the Mpumalanga province in northern South Africa is considered a qualifying facility. DTI representatives will be touring the facility in the first week of May.
According to the DTI website (http://www.thedti.gov.za/about_dti.jsp), their strategic objective is to facilitate transformation of the economy to promote industrial development, investment, competitiveness and employment creation. The grant for which Planda qualifies is based on a fixed percentage of actual capital invested in the project. Depending on the final cost of the Senteeko manufacturing facility and the percentage of award as determined by the legislature, the grant is expected to be between 14-26 million Rands ($1.3-2.5 million US). The final amount is expected to be determined over the coming 90 days with the award being paid later in 2014.
Chairman and Chief Executive Officer Roger Duffield commented, "The South African government has been among our strongest supporters, first with the $13 million government-backed loan from the Land and Agriculture Bank, and now with an additional $1.3 to $2.5 million grant to help defray the cost of building our production facility. It is a testament to their belief not only in our technology but also our efforts to revitalize the region by creating jobs and operating under a zero carbon footprint model. The grant money will be useful in supporting our operations as the factory comes online and sales begin to ramp up in the coming months."
Planda first product to market will be Phytofare Catechin Complex, which includes the entire catechin profile derived from live green tea that is grown and processed on the Company's 8,000 acre Senteeko estate in South Africa. Later in 2014, and pending the results of a human clinical trial for treating cold and flu symptoms, the Company will begin producing Phytofare Limonoid Glycoside Complex, which contains citrus bioflavonoids that will also be extracted at the Senteeko facility using lemons bought from neighboring farms until its own lemon trees reach maturity.
About Planda Biotechnology, Inc.
Planda Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Planda Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Safe Harbor Statement
The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Planda's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Planda is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.
Contact: Andrew BeyerPhone: 888-627-6902Email: investor@Plandabiotech.com
SOURCE: Plandai Biotechnology, Inc.
Good Morning PLPL !
PLPL still on ALERT !!
Good morning Everyone !!
PLPL trying to head back to a dollar ! Let's see what this afternoon brings !!
$PLPL retrace...don't get left out on the next run...load Zone !!
$PLPL great entry here, this will bounce !!
exactly, PLPL will come back..no problem. always has !
Nice time to load, PLPL has a big history of bouncing !! big money to be made !!
nice bounce back for PLPL !
Epazz, Inc. (QB) (EPAZ) up 33.33% !!
Volume: 17,287,489
Hop-on Signs European Distributor
New Re-Medical CBD Patch ready for Distribution in Denmark
TEMECULA, CA--(Marketwired - Apr 7, 2014) - Hop-on, Inc. (OTC Pink: HPNN) (PINKSHEETS: HPNN) today is pleased to announce its subsidiary company, Re-Medical, has signed a distribution agreement for its CBD (Cannabidiol) transdermal patches with a distributor in Denmark.
The new distributor is successfully selling other hemp and now Re-Medical CBD patch products. The timed release of CBD in the Re-Med patch represents a new generation of transdermal patch technology that combines superior bioavailability and excellent absorption rates with the highest effective levels of key nutritional supplements. A key to the importance of a nutritional supplement is its bioavailability, a measure of the rate at which it enters the bloodstream and is circulated to the body's organs and tissues. http://www.re-medical.com/Products.aspx
CBD is the primary chemical in cannabis that provide medicinal benefit, also acting to suppress or balance the psychoactive effects of THC. CBD is a dominant defensive and healing medicine for many of the most serious diseases afflicting people today such as cancer, epilepsy, and Alzheimer's. It is also a great alternative for anybody that finds marijuana or other cannabis infused products too strong, or just wants access to the therapeutic effects of cannabis without its psychoactive properties.
Peter Michaels, President of Hop-on and its subsidiaries, stated "This is just the first of several worldwide distribution partners we are negotiating with. We are excited to have this distribution partner on board, and we are confident they will represent our brand, promote our brand and sell our product with the same vigor and enthusiasm we do here in the US. We are looking forward to the coming year with this distribution partner."
ABOUT HOP-ON, INC.
Hop-on, Inc. is a global ODM and OEM manufacturer of electronics, based in the United States. Over the past 20 years, Hop-on has successfully secured essential patents for mobile communications and computing technologies, and is respected for developing the world's first disposable cell phone. Hop-on's focus on smartphones and innovative mobile device applications is bringing cost friendly solutions to today's demanding world market. Hop-on is also diversified in delivering cannabis remedies. For more information, please visit www.hop-on.com, www.usacig.com, and www.re-medical.com
Safe Harbor
This press release contains forward looking statements pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements include risks and uncertainties that may cause the company's plans to change and are in no way intended to guarantee that the company will be successful in executing its plans. Hop-on, Inc. common stock currently trades on the over-the-counter "Pink Sheets" under the symbol HPNN. This press release in no way constitutes any recommendation regarding the securities of HPNN or its affiliates. Any person reading this press release is advised that this release should be considered in the light of all facts and circumstances regarding the business and financial condition and prospects of HPNN, and no inference has been made that this release contains all such information.
CONTACT:
For additional information, please contact
Peter Michaels
(949) 756-9008
Email contact@hop-on.com
Polaris Internationa (PIHN) up 75.00% !!!
Volume: 3,911,143
Good morning PLPL !
PLPL on ALERT again !!!!!